Advanced search×

Distinct functions of kainate receptors in the brain are determined by the auxiliary subunit Neto1.

Nat Neurosci 14(7):866-73 (2011) PMID 21623363 PMCID PMC3125417

Ionotropic glutamate receptors principally mediate fast excitatory transmission in the brain. Among the three classes of ionotropic glutamate receptors, kainate receptors (KARs) have a unique brain distribution, which has been historically defined by (3)H-radiolabeled kainate binding. Compared with recombinant KARs expressed in heterologous cells, synaptic KARs exhibit characteristically slow rise-time and decay kinetics. However, the mechanisms responsible for these distinct KAR properties remain unclear. We found that both the high-affinity binding pattern in the mouse brain and the channel properties of native KARs are determined by the KAR auxiliary subunit Neto1. Through modulation of agonist binding affinity and off-kinetics of KARs, but not trafficking of KARs, Neto1 determined both the KAR high-affinity binding pattern and the distinctively slow kinetics of postsynaptic KARs. By regulating KAR excitatory postsynaptic current kinetics, Neto1 can control synaptic temporal summation, spike generation and fidelity.

DOI: 10.1038/nn.2837
Version: za2963e q8za6 q8zb1 q8zc2 q8zd0 q8zef q8zf7 q8zg6

Similar articles you may find interesting…

  1. Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display.

    Nucleic Acids Res 32(3):e36 (2004) PMID 14978223 PMCID 373425

    Homologous recombination in yeast can be exploited to reliably generate libraries of >10(7) transformants from a pool of PCR products and a linearized plasmid vector. Homology in the PCR insertion products drives shuffling of these genes in vivo by yeast homologous recombination. Two scFvs that shar...
  2. Managed competition for Medicare? Sobering lessons from The Netherlands.

    N Engl J Med 365(4):287-9 (2011) PMID 21675914

  3. Bevacizumab-induced hypertension: pathogenesis and management.

    BioDrugs 25(3):159-69 (2011) PMID 21627340

    Bevacizumab, a recombinant humanized monoclonal antibody targeting the vascular endothelial growth factor (VEGF), has been approved in the US as first- and second-line treatment of colorectal cancer and in the first-line treatment of advanced non-small cell lung cancer. The US FDA has also granted ap...